Boston Scientific is trading 4.1% down at $42.82 as investors react to reduced growth guidance and segment slowdowns.
- Management lowered full-year organic growth and Q2 outlooks, citing weaker trends in the WATCHMAN, Electrophysiology, and Urology divisions.
- Recent analyst downgrades and price target cuts have added pressure to the stock, compounded by broader healthcare sector weakness.